Connect with us

Marknadsnyheter

Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers

Published

on

Approvals based on significant survival benefits in HIMALAYA, POSEIDON and TOPAZ-1 Phase III trials.

AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung.

The approvals authorise Imfinzi in combination with Imjudo for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) and for the treatment of adult patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in combination with chemotherapy. Imfinzi was also authorised for the treatment of adult patients with unresectable HCC as monotherapy and for the treatment of adult patients with curatively unresectable biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the HIMALAYA and TOPAZ-1 Phase III trials, each published in the New England Journal of Medicine Evidence and the POSEIDON Phase III trial, published in the Journal of Clinical Oncology.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Japan has one of the highest rates of diagnosis for liver and biliary tract cancers in the world, and lung cancer remains the country’s leading cause of cancer death. With these approvals for Imfinzi and Imjudo, patients in Japan can now be treated with novel immunotherapy-based treatment regimens that have demonstrated significant survival benefits across three complex cancers with poor prognoses.”

Imfinzi and Imjudo approved in liver cancer
The approval of Imfinzi in combination with Imjudo for the treatment of unresectable HCC brings the first dual immunotherapy treatment regimen to patients in Japan. The approval is based on results from the HIMALAYA Phase III trial, in which a single dose of the anti-CTLA-4 antibody Imjudo 300mg added to the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks (STRIDE regimen: Single Tremelimumab Regular Interval Durvalumab) significantly reduced the risk of death versus sorafenib. The addition of Imjudo to Imfinzi did not increase severe liver toxicity, and no bleeding risk was observed.

HIMALAYA also served as the basis for the approval of Imfinzi monotherapy in the same disease setting. In HIMALAYA, Imfinzi demonstrated non-inferior overall survival (OS) compared to sorafenib, and an improved tolerability profile versus sorafenib.

The safety profiles of the combination of Imjudo added to Imfinzi and for Imfinzi alone were consistent with the known profiles of each medicine, and no new safety signals were identified.

Liver cancer is the fifth-leading cause of cancer death in Japan and the sixth most commonly diagnosed cancer worldwide.1,2 HCC is the most common type of liver cancer with 80% of cases occurring in the Asia-Pacific region.3,4 In Japan, approximately 45,000 people are diagnosed with HCC and 32,000 die of the disease each year.5,6

Imfinzi and Imjudo approved in NSCLC
The approval of Imfinzi and Imjudo plus chemotherapy for the treatment of unresectable, advanced or recurrent NSCLC is based on results from the POSEIDON Phase III trial, which showed a limited course of five cycles of the anti-CTLA-4 antibody Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy significantly reduced the risk of death versus a range of chemotherapy options.

The safety profile for Imjudo plus Imfinzi and chemotherapy was consistent with the known profiles of each medicine, and no new safety signals were identified.

In Japan, lung cancer is the most commonly diagnosed cancer, with more than 138,000 patients diagnosed in 2020.1 The prognosis for patients with metastatic NSCLC in Japan is particularly poor, as less than 20% will live beyond three years after diagnosis without treatment.7

Regulatory applications for Imfinzi and Imjudo are currently under review in the EU and several other countries based on the HIMALAYA, TOPAZ-1 and POSEIDON results.

Imfinzi plus chemotherapy approved in biliary tract cancer
The approval of Imfinzi plus chemotherapy brings the first immunotherapy regimen to patients with curatively unresectable BTC in Japan after more than a decade of limited innovation. The approval is based on results from an interim analysis of the TOPAZ-1 Phase III trial, which showed that Imfinzi plus chemotherapy significantly reduced the risk of death compared to chemotherapy alone. Imfinzi plus chemotherapy was generally well tolerated and did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.

BTC is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder.8,9 In 2021, approximately 23,300 people in Japan were diagnosed with BTC, which is the sixth-leading cause of cancer-related deaths for women and seventh-leading cause of cancer-related death for men in Japan.7 Patients face a poor prognosis, with approximately 19% to 31% of patients with BTC surviving five years.7

Notes

HIMALAYA
HIMALAYA was a randomised, open-label, multicentre, global Phase III trial of Imfinzi monotherapy and the STRIDE regimen comprising a single priming dose of Imjudo 300mg added to Imfinzi 1500mg followed by Imfinzi every four weeks versus sorafenib, a standard-of-care multi-kinase inhibitor.

The trial included a total of 1,324 patients with unresectable, advanced HCC who had not been treated with prior systemic therapy and were not eligible for locoregional therapy (treatment localised to the liver and surrounding tissue).

The trial was conducted in 181 centres across 16 countries, including in the US, Canada, Europe, South America and Asia. The primary endpoint was OS for the combination versus sorafenib and key secondary endpoints included OS for Imfinzi versus sorafenib, objective response rate (ORR) and progression-free survival (PFS) for the combination and for Imfinzi alone.

In HIMALAYA, the STRIDE regimen reduced the risk of death by 22% versus sorafenib (hazard ratio [HR] 0.78; 95% confidence interval [CI], 0.66-0.92; p= 0.0035). An estimated 31% of patients treated with the combination were still alive after three years, with 20% of patients treated with sorafenib still alive at the same duration of follow-up. The safety profiles of the combination of Imjudo added to Imfinzi and for Imfinzi alone were consistent with the known profiles of each medicine, and no new safety signals were identified.

POSEIDON
The POSEIDON trial was a randomised, open-label, multi-centre, global, Phase III trial of Imfinzi plus platinum-based chemotherapy, or Imfinzi, Imjudo and chemotherapy, versus chemotherapy alone in the 1st-line treatment of 1,013 patients with metastatic NSCLC. The trial population included patients with either non-squamous or squamous disease, and the full range of PD-L1 expression levels. POSEIDON excluded patients with certain epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions.

In the experimental arms, patients were treated with a flat dose of either Imfinzi (1,500mg) or Imfinzi plus Imjudo (75mg) with up to four cycles of chemotherapy every three weeks before either Imfinzi maintenance once every four weeks or Imfinzi and a fifth dose of Imjudo given at week 16. In comparison, the control arm allowed up to six cycles of chemotherapy. Pemetrexed maintenance treatment was allowed in all arms in patients with non-squamous disease if given during the induction phase. Nearly all patients with non-squamous disease (95.5%) had pemetrexed and platinum, while the majority of patients with squamous disease receiving chemotherapy (88.3%) received gemcitabine and platinum.

Primary endpoints included PFS and OS for the Imfinzi plus chemotherapy arm. Key secondary endpoints included PFS and OS in the Imfinzi plus Imjudo and chemotherapy arm. As both PFS endpoints were met for Imfinzi plus chemotherapy and Imfinzi, Imjudo and chemotherapy, the prespecified statistical analysis plan allowed for testing OS in the Imfinzi plus Imjudo and chemotherapy arm. The trial was conducted in more than 150 centres across 18 countries, including the US, Europe, South America, Asia and South Africa.

Patients treated with a limited course of five cycles of the anti-CTLA-4 antibody Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options (HR 0.77; 95% CI, 0.65-0.92; p=0.00304). An estimated 33% of patients were alive at two years versus 22% for chemotherapy. This treatment combination also reduced the risk of disease progression or death by 28% compared to chemotherapy alone (HR 0.72; 95% CI, 0.60-0.86; p=0.00031).

Updated results after approximately four years of follow-up presented at the European Society for Medical Oncology Congress 2022 demonstrated sustained survival benefit, improving overall survival (OS) by 25% compared to chemotherapy alone (HR 0.75; 95% CI, 0.63-0.88). An estimated 25% of patients treated with the combination were alive at three years versus 13.6% for those treated with chemotherapy alone. The safety profile for Imjudo plus Imfinzi and chemotherapy was consistent with the known profiles of each medicine, and no new safety signals were identified.

TOPAZ-1
TOPAZ-1 was a randomised, double-blind, placebo controlled, multicentre, global Phase III trial of Imfinzi in combination with chemotherapy (gemcitabine plus cisplatin) versus placebo in combination with chemotherapy as a 1st-line treatment in 685 patients with unresectable advanced or metastatic BTC including intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer. Patients with ampullary carcinoma were excluded.

The primary endpoint was OS and key secondary endpoints included PFS, ORR and safety. The trial was conducted in 105 centres across 17 countries including in the US, Europe, South America and several countries in Asia including South Korea, Thailand, Japan and China.

At the interim analysis, Imfinzi plus chemotherapy reduced the risk of death by 20% versus chemotherapy alone (based on a hazard ratio [HR] of 0.80; 95% confidence interval [CI] 0.66-0.97; p=0.021). Updated results from TOPAZ-1 after an additional 6.5 months of follow-up showed a 24% reduction in the risk of death versus chemotherapy alone (HR 0.76; 95% CI, 0.64-0.91), with more than two times as many patients treated with Imfinzi plus chemotherapy estimated to be alive at two years versus chemotherapy alone (23.6% versus 11.5%). Updated median overall survival (OS) was 12.9 months versus 11.3 with chemotherapy. Imfinzi plus chemotherapy was generally well tolerated, with no new safety signals observed, and did not increase the discontinuation rate due to adverse events (AEs) compared to chemotherapy alone.

Imfinzi
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy and is the global standard of care in this setting based on the PACIFIC Phase III trial.

Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer (ES-SCLC) based on the CASPIAN Phase III trial. In 2021, updated results from the CASPIAN trial showed Imfinzi plus chemotherapy tripled patient survival at three years versus chemotherapy alone.

Imfinzi is also approved in combination with Imjudo and chemotherapy in metastatic non-small cell lung cancer in the US and Japan; in combination with chemotherapy in locally advanced or metastatic BTC in the US, Japan and several other countries; in combination with Imjudo in unresectable HCC in the US and Japan; as monotherapy in unresectable HCC in Japan; and in previously treated patients with advanced bladder cancer in several countries.

Since the first approval in May 2017, more than 100,000 patients have been treated with Imfinzi.

As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, bladder cancer, several gastrointestinal (GI) cancers, ovarian cancer, endometrial cancer and other solid tumours. 

Imjudo
Imjudo (tremelimumab) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death.

In addition to its approved indications in liver and lung cancers, Imjudo is being tested in combination with Imfinzi across multiple tumour types including locoregional HCC (EMERALD-3), SCLC (ADRIATIC) and bladder cancer (VOLGA and NILE).

AstraZeneca in GI cancers
AstraZeneca has a broad development programme for the treatment of GI cancers across several medicines and a variety of tumour types and stages of disease. In 2020, GI cancers collectively represented approximately 5.1 million new cancer cases leading to approximately 3.6 million deaths.10

Within this programme, the Company is committed to improving outcomes in gastric, liver, BTC, oesophageal, pancreatic, and colorectal cancers.

Imfinzi is approved in the US and several other countries in combination with chemotherapy (gemcitabine plus cisplatin) for advanced biliary tract cancer and in the US and Japan in combination with Imjudo in unresectable HCC. Imfinzi is also approved as a monotherapy in unresectable HCC in Japan. Imfinzi is being assessed in combinations, including with Imjudo, in liver, oesophageal and gastric cancers in an extensive development programme spanning early to late-stage disease across settings.

Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate, is approved in the US and several other countries for HER2-positive advanced gastric cancer and is being assessed in colorectal cancer. Enhertu is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Lynparza (olaparib), a first-in-class PARP inhibitor, is approved in the US and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. inside the US and Canada).

AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.

The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu and datopotamab deruxtecan in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.

AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.

AstraZeneca in immuno-oncology (IO)
AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours.

AstraZeneca aims to reimagine cancer care and help transform outcomes for patients with Imfinzi as a single treatment and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also exploring next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer.

AstraZeneca is boldly pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure.

AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References 

  1. World Health Organization. Japan Fact Sheet. Available at: https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf. Accessed December 2022.
  2. World Health Organization. Liver Cancer Fact Sheet. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed December 2022.
  3. ASCO. Liver Cancer: View All Pages. Available at: https://www.cancer.net/cancer-types/liver-cancer/view-all. Accessed December 2022.
  4. Boyle DA. Hepatocellular carcinoma: Implications for Asia-Pacific Oncology Nurses. Asia Pac J Oncol Nurs. 2017;(4)2.98-103.
  5. World Health Organization. International Agency for Research on Cancer. Estimated number of new cases in 2020, Japan, both sexes, all ages (excl. NMSC). Available at: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=392&populations=392&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&. Accessed December 2022.
  6. Ikeda M, et al. Current status of hepatocellular carcinoma in Japan. Chin Clin Oncol. 2013;2(4):40.
  7. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan – 2022. Available at: https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2022.pdf. Accessed December 2022.
  8. Marcano-Bonilla L, et al. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. CCO. 2016;5(5).
  9. ESMO. What is Biliary Tract Cancer. Available at: https://www.esmo.org/content/download/266801/5310983/1/EN-Biliary-Tract-Cancer-Guide-for-Patients.pdf. Accessed December 2022.
  10. World Health Organization. World Cancer Fact Sheet. Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 2022.
Continue Reading
Click to comment

Leave a Reply

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *

Marknadsnyheter

Safe Lane Gaming förstärker sin ledningsgrupp

Published

on

By

Safe Lane Gaming förstärker ledningsgruppen med Johan Henkow som Chief Operating Officer och Per Ekstig som Chief Technology Officer. 

Vår kommunicerade satsning på egenutvecklade spel inom Hyper Casual kräver att vi har personer med rätt kompetens och erfarenhet som jobbar över hela Safe Lane Gamings spelportfölj. Det känns väldigt bra att både Johan och Per nu ingår i ledningsgruppen då deras input och engagemang är en central del för SLGs arbete framåt, säger Arvid Klingström VD för Safe Lane Gaming

Både Johan och Per har arbetat många år på Raketspel och har varit drivande vid spelsläpp och vidareutveckling av bolagets mest framgångsrika spel. Tillträde i de nya rollerna sker med omedelbar verkan och ledningsgruppen utgörs nu av Philip Arfwedson CFO, Johan Henkow COO, Per Ekstig CTO och Arvid Klingström CEO

För mer information, vänligen kontakta Bolaget på:
Arvid Klingström
Telefon: +46 768 54 46 50
[email protected]
www.safelanegaming.com

Safe Lane Gaming AB (publ) är ett bolag inom mobilspelsindustrin med över 10 spel portföljen. Utöver spelutveckling fokuserar bolaget på strategiska förvärv och organisk tillväxt. Bolaget utvecklar, förvaltar och förvaltar spel för samtliga plattformar (främst iOS och Android)

Continue Reading

Marknadsnyheter

Copernicus: Exceptionellt varmt – Europas tredje varmaste januarimånad; lägsta utbredningen av havsis i Antarktis i januari

Published

on

By

Copernicus

Yttemperaturavvikelse för januari 2023 i förhållande till januarigenomsnittet för perioden 1991-2020. Datakälla: ERA5. Källa: Copernicus Climate Change Service/ECMWF.

Copernicus Climate Change Service (C3S), implementerat av European Centre for Medium Range Weather Forecasts på uppdrag av Europeiska kommissionen, publicerar rutinmässigt månatliga klimatbulletiner som rapporterar om förändringar som observerats i den globala ytlufttemperaturen, havsisen och hydrologiska variabler. Alla de rapporterade fynden är baserade på datorgenererade analyser med hjälp av miljarder mätningar från satelliter, fartyg, flygplan och väderstationer runt om i världen. 

Temperaturer i januari 2023:

  • Januari 2023 var den 3:e varmaste i Europa
  • En stor del av Europa hade lufttemperaturer över genomsnittet, särskilt på Balkan och i östra Europa, där rekordvärme uppmättes på nyårsdagen; det var också ovanligt varmt i Svalbardregionen
  • Temperaturer över genomsnittet uppmättes i östra USA, Kanada, Mexiko och i ett band från sydöstra till nordvästra Ryssland
  • Temperaturer under genomsnittet uppmättes i Sibirien, Afghanistan, Pakistan och angränsande länder samt Australien

Copernicus

Månatliga globala medel- och europeiska medeltemperaturavvikelser i förhållande till 1991-2020, från januari 1979 till januari 2023. De mörkare färgade staplarna anger januarivärdena. Datakälla: ERA5. Källa: Copernicus Climate Change Service/ECMWF.

Havsisläget i januari 2023:

  • Antarktis havsisutbredning nådde sin lägsta utbredning för januari i satellitmätningen, 31 procent under genomsnittet, långt under det tidigare rekordet från januari 2017.
  • Havsiskoncentrationer under genomsnittet rådde i alla delar av södra oceanen.
  • Arktis havsisutbredning var 4 procent under genomsnittet, rankad 3:e lägsta uppmätta i januari.
  • Havsiskoncentrationerna i Arktis var mest under genomsnittet i Barents hav och Svalbardregionen.

Copernicus

Vänster: Genomsnittlig arktisk havsiskoncentration för januari 2023. Den tjocka orange linjen betecknar den klimatologiska havsiskanten för januari för perioden 1991-2020. Till höger: Anomali i arktisk havsiskoncentration för januari 2023 i förhållande till januarigenomsnittet för perioden 1991-2020. Datakälla: ERA5. Källa: Copernicus Climate Change Service/ECMWF.

enligt Samantha Burgess, Biträdande direktor för C3S, ”Många av oss upplevde de exceptionellt varma temperaturerna runt årsskiftet. Även om januari 2023 var exceptionellt, förblir dessa extrema temperaturer en påtaglig indikation på effekterna av ett förändrat klimat för många regioner och kan uppfattas som en ytterligare varning för framtida extrema händelser. Det är absolut nödvändigt att vidta snabba åtgärder för att mildra de ökande globala temperaturerna.”

Rekordtemperaturer på nyårsdagen 2023

Copernicus

Daglig genomsnittlig ytlufttemperaturanomali för 1 januari 2023 i förhållande till genomsnittet under perioden 17 december-16 januari för vintrarna 1990/1991 till 2019/2020. Datakälla: ERA5. Källa: Copernicus Climate Change Service/ECMWF.

Videomaterial som medföljer kartorna finns här.

Mer information om klimatvariationer i oktober och klimatuppdateringar från tidigare månader, högupplöst grafik och video kan laddas ned här.

Svar på ofta ställda frågor om temperaturövervakning finns här.

Information om C3S data set och hur det sammanställs

Temperatur- och hydrologikartor samt data är från ECMWF Copernicus Climate Change Services ERA5-data.

Havsiskartor och data är från en kombination av information från ERA5, såväl som från EUMETSAT OSI SAF Sea Ice Index v2.1, Sea Ice Concentration CDR/ICDR v2 och snabbspårdata som tillhandahålls på begäran av OSI SAF.

Regionala medelvärden som anges har följande longitud/latitudgränser:
Hela jorden, 180W-180E, 90S-90N. totalt.
Europa, 25W-40E, 34N-72N, endast över land. 

Mer information finns här.

Information om nationella data och inverkan

Information om nationella data och inverkan baseras på nationella och regionala rapporter. För detaljer se respektive månads temperatur och hydrologisk C3S klimatbulletin.

C3S har följt Världsmeteorologiska organisationens (WMO) rekommendation att använda den senaste 30-årsperioden för att beräkna klimatologiska medelvärden och ändrat till referensperioden 1991-2020 för sina C3S Climate Bulletins som täcker januari 2021 och framåt. Figurer och grafik för både den nya och föregående perioden (1981-2010) tillhandahålls för transparens.

Mer information om den använda referensperioden finns här

Om Copernicus och ECMWF

Copernicus är en del av Europeiska unionens rymdprogram, med finansiering från EU, och är dess flaggskeppsprogram för jordobservation. Verksamheten fungerar genom sex tematiska tjänster: Atmosfär, marina, mark, klimatförändringar, säkerhet och nödsituationer. Den levererar fritt tillgängliga driftsdata och tjänster som ger användarna tillförlitlig och aktuell information om vår planet och dess miljö. Programmet samordnas och hanteras av EU-kommissionen och genomförs i partnerskap med medlemsstaterna, European Space Agency (ESA), European Organization for Exploitation of Meteorological Satellites (EUMETSAT), European Center for Medium-Distance Weather Forecasts ( ECMWF), EU-byråer och Mercator Océan, med flera.

ECMWF driver två tjänster från EU: s Copernicus Earth observationsprogram: Copernicus Atmosphere Monitoring Service (CAMS) och Copernicus Climate Change Service (C3S). De bidrar också till Copernicus Emergency Management Service (CEMS), som genomförs av EU:s gemensamma forskningsråd (JRC). European Center for Medium-Range Weather Forecasts (ECMWF) är en oberoende mellanstatlig organisation som stöds av 35 stater. Det är både ett forskningsinstitut och en operativ tjänst 24/7 som producerar och sprider numeriska väderprognoser till sina medlemsstater. Dessa uppgifter är fullt tillgängliga för de nationella meteorologiska tjänsterna i medlemsstaterna. Superdatoranläggningen (och tillhörande dataarkiv) på ECMWF är en av de största i sin typ i Europa och medlemsstaterna kan använda 25 procent av sin kapacitet för sina egna ändamål

ECMWF har utökat antalet platser där man bedriver verksamhet. Förutom huvudkontoret i Storbritannien och Computing Center i Italien kommer nya kontor med fokus på aktiviteter som genomförs i partnerskap med EU, såsom Copernicus, finns i Bonn, Tyskland. 

 
Copernicus Atmosphere Monitoring Service webb  http://atmosphere.copernicus.eu/ 

Copernicus Climate Change Service webb https://climate.copernicus.eu/ 

Mer information om Copernicus: www.copernicus.eu 

ECMWF:s webb: https://www.ecmwf.int/ 

Twitter: 
@CopernicusECMWF 
@CopernicusEU 
@ECMWF 

#EUSpace 

Mediekontakt

Nuria Lopez
Communications | Copernicus Contracts and Press
Office of the Director General
European Centre for Medium-Range Weather Forecasts
Reading, UK | Bologna, Italy
Email: [email protected]
Phone: +44 (0)118 949 9778
Mobile: +44 (0)7392 277 523
Twitter: @CopernicusECMWF

Björn Mogensen
+46 708-184298
[email protected]

Taggar:

Continue Reading

Marknadsnyheter

Eternali bjuder in till digital investerarträff den 13 februari 2023

Published

on

By

Skogsaktiebolaget Eternali (publ) (”Eternali” eller ”Bolaget”) bjuder in till en digital investerarträff den 13 februari 2023 med anledning av den nyemission av units som nu genomförs med teckningstid till och med den 17 februari 2023.

Investerarträffen genomförs i form av en livesänd presentation där Eternalis VD, Andreas Forssell, presenterar Bolaget samt informerar om den pågående nyemissionen. Deltagare erbjuds att ställa frågor digitalt. Den livesända presentationen hålls på svenska.

Tid: 13 februari 2023 kl 13.30 – 14.30.

Livesändning och registrering till träffen hänvisas till följande länk: Eternali aktieägarträff och pågående nyemission av units, 13 februari 2023 (financialhearings.com)

För mer information om nyemissionen av units: Unit issue – investors 2023 (eternali.se)

För mer information kontakta:

Andreas Forssell, CEO
mob: +46 76 015 15 95
mail: 
[email protected]

​​​​​Tim Carlsson, CFO
mob: +46 70 231 87 01
mail: 
[email protected]

Om Eternali
Eternali är ett skogsbolag med fokus att vara en aktör i den globala värdekedjan för snabbväxande träfiber som råvara. Vår vision är att skapa värde i den gröna omställningen. Eternali är verksamma med huvudkontor i Stockholm, Sverige. Produktionen och den operativa verksamheten är placerad i norra Brasilien, med huvudkontor i Belém, Brasilien och operativ verksamhet i Urbano Santos, Brasilien. Eternali är ansluten till FN Global Compact och följer dess principer för ett ansvarsfullt företagande. För mer information besök Eternalis hemsida eternali.se.

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.